SARCOMATOID RENAL CELL CARCINOMA

This phase 3 trial tests whether adding the immune-boosting drug nivolumab before and after kidney cancer surgery can prevent the cancer from coming back. About 819 patients with localized kidney cancer are randomly assigned to receive either surgery alone or surgery plus nivolum…

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the co…

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…